NOTCH1 mutation
NOTCH1 mutation
|
Prolymphocytic Leukemia
Prolymphocytic Leukemia
|
ibrutinib
Resistant: C3 – Early Trials
|
JAK3 mutation
JAK3 mutation
|
Prolymphocytic Leukemia
Prolymphocytic Leukemia
|
venetoclax + ruxolitinib
Sensitive: C3 – Early Trials
|
CDKN2A deletion
CDKN2A deletion
|
Prolymphocytic Leukemia
Prolymphocytic Leukemia
|
alemtuzumab
Resistant: C4 – Case Studies
|
STAT5B N642H
STAT5B N642H
|
Prolymphocytic Leukemia
Prolymphocytic Leukemia
|
alemtuzumab
Resistant: C4 – Case Studies
|
TCL1A rearrangement
TCL1A rearrangement
|
Prolymphocytic Leukemia
Prolymphocytic Leukemia
|
alemtuzumab
Resistant: C4 – Case Studies
|
|
Prolymphocytic Leukemia
Prolymphocytic Leukemia
|
alemtuzumab
Resistant: C4 – Case Studies
|
|
Prolymphocytic Leukemia
Prolymphocytic Leukemia
|
alemtuzumab
Resistant: C4 – Case Studies
|
PAK4 deletion
PAK4 deletion
|
Prolymphocytic Leukemia
Prolymphocytic Leukemia
|
alemtuzumab
Resistant: C4 – Case Studies
|
|
Prolymphocytic Leukemia
Prolymphocytic Leukemia
|
alemtuzumab
Resistant: C4 – Case Studies
|
|
Prolymphocytic Leukemia
Prolymphocytic Leukemia
|
venetoclax
Resistant: C4 – Case Studies
|
|
Prolymphocytic Leukemia
Prolymphocytic Leukemia
|
dasatinib
Resistant: C4 – Case Studies
|
|
Prolymphocytic Leukemia
Prolymphocytic Leukemia
|
vemurafenib
Sensitive: C4 – Case Studies
|
